YOLFTbeta
01

Seoul Pharma Co. Ltd

018680 · KQ · Healthcare / Drug Manufacturers - Specialty & Generic

1,798.00KRW+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close1,798.00
Open1,781.00
Day Range1,727.00 – 1,798.00
52-Week Range1,820.00 – 3,310.00
Volume3.64K
Market Cap22.60B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.50
50-Day Avg1,977.26
200-Day Avg2,498.67

About

Seoul Pharma Co., Ltd manufactures and sells pharmaceutical products in South Korea and internationally. The company offers orally disintegrating film products for therapeutic areas, including urology, neurology, nutrition, endocrinology, and OB/GY. Its products include VULTEUM and VULTIS for erectile dysfunction; ARTPEZIL for Alzheimer' disease; OBCARE to treat overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency; and CH.V, as well as products for schizophrenia, vitamin supplement, obesity, tonic, and menopausal syndrome. The company also provides Ator for high blood pressure treatment; Flavel to treat stroke; Axated, a peptic ulcer medication; Crestin to treat hyperlipidemia; and Weltmin and Fendigene for the treatment of obesity. It also owns patents to orally dispersible films. The company was founded in 1976 and is headquartered in Cheongju-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOHei Youn Hwang
  • Employees0
  • Headquarters124-31, Osongsaengmyeong 6-ro, Cheongju-si, South Korea, 281 58, Korea
  • Websitehttps://www.seoulpharma.com

Leadership

  • Hei Youn HwangCEO & Director

Financials

Income Statement

Currency: KRW2007-12-312008-12-312009-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue----46.38B42.04B43.82B44.73B45.92B46.65B44.14B53.95B52.23B40.46B50.06B52.46B53.58B52.15B
Growth (%)------9.35%+4.22%+2.09%+2.66%+1.59%-5.38%+22.22%-3.19%-22.53%+23.71%+4.80%+2.14%-2.67%
Cost of Revenue----20.11B20.29B21.28B22.82B21.25B20.53B21.16B23.35B17.00B14.98B17.91B20.87B20.65B20.65B
Gross Profit----26.26B21.75B22.54B21.91B24.67B26.12B22.98B30.60B35.23B25.48B32.15B31.59B32.93B31.50B
Gross Margin----56.63%51.73%51.44%48.97%53.72%55.99%52.06%56.73%67.45%62.98%64.22%60.21%61.46%60.41%
Operating Expense----20.16B20.41B21.86B21.24B22.14B24.03B26.73B27.10B24.92B31.40B32.58B30.37B31.40B32.78B
Operating Income----6.10B1.33B677.35M670.24M2.52B2.09B-3.75B3.51B10.31B-5.91B-438.07M1.21B1.53B-1.28B
Operating Margin----13.16%3.18%1.55%1.50%5.50%4.49%-8.49%6.50%19.74%-14.61%-0.88%2.31%2.85%-2.45%
EBITDA--------------2.62B6.41B4.69B3.87B
EBITDA Margin--------------5.23%12.23%8.76%7.42%
Net Income----5.10B618.00M-695.97M-783.06M816.80M881.44M-4.35B-1.87B-1.34B-9.69B855.09M3.52B1.70B753.64M
Net Income Margin----11.00%1.47%-1.59%-1.75%1.78%1.89%-9.86%-3.46%-2.57%-23.94%1.71%6.70%3.17%1.45%
R&D------------2.73B6.37B3.26B3.14B2.62B2.75B
R&D as % of Total Revenue------------5.23%15.74%6.52%5.99%4.89%5.28%
Interest Expense000000000001.39B1.24B1.13B1.12B442.51M442.12M577.29M
Interest Expense % of Total Revenue----0.00%0.00%0.00%0.00%0.00%0.00%0.00%2.58%2.37%2.80%2.25%0.84%0.83%1.11%

Balance Sheet

Currency: KRW2007-12-312008-12-312009-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets----60.68B71.42B78.98B82.68B92.54B86.93B90.57B70.89B65.09B62.25B62.43B63.31B71.62B71.75B
Total Liabilities----35.29B39.17B47.88B49.15B50.47B33.08B40.25B42.44B36.23B43.29B27.01B24.74B31.45B30.70B
Total Equity------31.10B33.53B42.07B53.86B50.31B28.45B28.85B18.96B35.42B38.56B40.17B41.05B
Cash----3.25B164.00M3.92B9.37B3.26M4.43B763.00K7.67B15.06B13.82B11.73B6.57B7.54B9.95B
Total Debt-------32.69B38.93B9.78B19.83B15.58B16.67B-----
Net Debt------------10.30B14.23B2.27B3.43B5.46B5.05B

Cash Flow

Currency: KRW2007-12-312008-12-312009-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.13B-755.68M1.23B4.86B9.22B-425.00M1.48B1.42B-1.89B-1.14B-1.23B2.93B5.74B-1.67B-78.21M5.26B-3.01B1.89B
Investing Cash Flow-1.86B-3.03B-6.20B-6.56B-20.23B-11.52B-3.73B-1.43B-6.64B5.37B-4.19B3.32B-293.15M-1.10B-1.33B-5.86B1.46B-
Financing Cash Flow1.64B4.20B4.16B3.59B11.71B8.86B6.01B5.46B8.89B-9.55B5.73B-3.31B2.00B1.54B-483.19M-4.47B2.38B-
Capital Expenditure1.76B2.33B6.11B5.43B17.95B10.54B2.62B1.40B6.22B1.60B599.64M156.43M671.25M1.17B1.30B1.89B2.23B893.72M
Free Cash Flow------------5.07B-2.84B-1.38B3.37B-5.24B992.07M
Dividends Paid187.50M312.50M312.50M312.50M--342.89M240.02M177.95M111.01M125.77M-127.28M00---
FCF to OCF------------88.30%169.72%1760.88%64.02%174.11%52.61%
Dividend Paid to FCF------------2.51%0.00%0.00%---

Earnings

Report DateMar 31, 2009Jun 30, 2009Sep 30, 2009Dec 31, 2009Mar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Nov 14, 2017Feb 12, 2018May 15, 2018Aug 14, 2018Nov 14, 2018Feb 13, 2019May 14, 2019Aug 13, 2019Nov 10, 2019Feb 11, 2020Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate----------------------------------------------------------------------
EPS Actual27.0040.26-5.88127.5754.8193.3131.5918.4664.6582.0032.3834.3146.6570.5516.66678.2351.12-125.00-12.68131.2430.3222.57-19.77-134.6028.66-2.62-147.8312.83-33.86-95.0074.00-552.2870.84-126.00-166.36320.06-46.28-124.00-280.23-63.71-23.8181.6113.47-44.47-438.98-47.90909.00-715.38-281.46-156.12-100.00-599.02-26.30-4.3671.7754.10298.827.35-36.9232.4250.8423.3214.8456.70-14.08-114.13225.07-32.22-16.46-27.25
Surprise----------------------------------------------------------------------
Timing----------------------------------Pre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hours-After-hoursAfter-hours--------------------------

Key Statistics & Ratios

Market Cap22.60B
Enterprise Value20.95B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.44
Price / Book0.56
Revenue (TTM)51.08B
Gross Profit (TTM)30.32B
EBITDA1.88B
Profit Margin3.40%
Operating Margin-2.92%
Return on Equity4.39%
Return on Assets-0.69%
Shares Outstanding11.66M
Shares Float4.72M
Beta0.50
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20201×
15.00Dec 29, 2020
20191×
15.00Dec 27, 2019
20171×
15.00Dec 27, 2017
20161×
15.00Dec 28, 2016
20151×
25.00Dec 29, 2015
20141×
35.00Dec 29, 2014
20131×
50.00Dec 27, 2013
20121×
60.00Dec 27, 2012
20111×
60.00Dec 28, 2011
20101×
50.00Dec 29, 2010
20091×
40.00Dec 29, 2009
20061×
30.00Dec 27, 2006
20051×
30.00Dec 28, 2005
20041×
75.00Dec 29, 2004
20031×
60.00Dec 29, 2003
20021×
60.00Dec 27, 2002
20012×
60.00Dec 27, 200160.00Jan 2, 2001

Stock Splits

  • Apr 12, 20042:1
  • Nov 11, 20025:1